Perspectives on the Future on Myelofibrosis Treatment

Opinion
Video

Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.

Case: A 63-Year-Old Man with Myelofibrosis

Clinical Presentation:

  • A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
  • PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)

Follow up and Clinical Workup at 3 Months:

  • Exam: night sweats improved.
  • Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
  • Some spleen reduction.
  • Patient receives ~1 unit RBC per month.

Follow up and Clinical Workup at 6 Months:

  • Patient reports complaints of fatigue and abdominal pain.
  • Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
  • Patient now receives 2 units RBC per month.
  • Experienced recurrence of SCC.
Related Videos
Video 2 - "Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease"
Video 1 - "Patient Case: Pathology of Graft Versus Host Disease"
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content